Nektar Therapeutics (NKTR)
NASDAQ: NKTR · Real-Time Price · USD
76.17
+0.67 (0.89%)
Aug 12, 2026, 11:04 AM EDT - Market open
Nektar Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 149.58 | 15.12 | 44.25 | 35.28 | 88.23 | 25.22 |
Short-Term Investments | 419.03 | 230.64 | 210.97 | 268.34 | 416.75 | 708.74 |
Cash & Short-Term Investments | 568.6 | 245.75 | 255.23 | 303.62 | 504.98 | 733.96 |
Cash Growth | 160.07% | -3.71% | -15.94% | -39.88% | -31.20% | -30.88% |
Accounts Receivable | - | - | - | 1.21 | 5.98 | 22.49 |
Inventory | - | - | - | 16.1 | 19.2 | 15.8 |
Other Current Assets | 20.44 | 20.51 | 6.07 | 9.78 | 15.81 | 23.33 |
Total Current Assets | 589.04 | 266.27 | 261.29 | 330.7 | 545.97 | 795.58 |
Net Property, Plant & Equipment | - | 5 | 11.82 | 36.86 | 85.89 | 177.54 |
Goodwill | - | - | - | - | 76.5 | 76.5 |
Long-Term Investments | 162.99 | 3.49 | 26.09 | 25.83 | - | 64.83 |
Other Long-Term Assets | 11.24 | 5.65 | 4.65 | 4.64 | 2.25 | 2.74 |
Total Assets | 763.27 | 280.41 | 303.85 | 398.03 | 710.6 | 1,117 |
Accounts Payable | 10.03 | 10.77 | 11.56 | 9.85 | 12.98 | 9.75 |
Accrued Expenses | 25.15 | 22.27 | 29.97 | 22.16 | 36.56 | 58.01 |
Current Portion of Leases | 22.53 | 20.5 | 19.87 | 19.26 | 18.67 | 17.44 |
Total Current Liabilities | 57.71 | 53.54 | 61.4 | 51.27 | 68.2 | 85.2 |
Long-Term Leases | 60.63 | 65.26 | 82.7 | 98.52 | 112.83 | 125.74 |
Other Long-Term Liabilities | 68.72 | 71.78 | 99.02 | 117.26 | 162.93 | 226.75 |
Total Long-Term Liabilities | 129.35 | 137.04 | 181.71 | 215.78 | 275.76 | 352.48 |
Total Liabilities | 187.06 | 190.57 | 243.11 | 267.05 | 343.96 | 437.68 |
Common Stock | 0 | 0 | 0 | 0.02 | 0.02 | 0.02 |
Treasury Stock | - | - | -3 | - | - | - |
Additional Paid-in Capital | 4,382 | 3,850 | 3,660 | 3,608 | 3,575 | 3,517 |
Accumulated Other Comprehensive Income | -1.03 | 0.02 | 0.06 | 0.08 | -6.91 | -4.16 |
Retained Earnings | -3,805 | -3,760 | -3,596 | -3,477 | -3,201 | -2,833 |
Shareholders' Equity | 576.22 | 89.83 | 60.74 | 130.99 | 366.64 | 679.51 |
Total Liabilities & Equity | 763.27 | 280.41 | 303.85 | 398.03 | 710.6 | 1,117 |
Total Debt | 83.16 | 85.75 | 102.56 | 117.78 | 131.5 | 143.18 |
Net Cash (Debt) | 485.44 | 160 | 152.66 | 185.84 | 373.48 | 590.78 |
Net Cash Growth | 310.37% | 4.81% | -17.85% | -50.24% | -36.78% | -35.19% |
Net Cash Per Share | 24.87 | 9.48 | 11.13 | 14.67 | 29.94 | 48.35 |
Book Value | 576.22 | 89.83 | 60.74 | 130.99 | 366.64 | 679.51 |
Book Value Per Share | 29.52 | 5.32 | 4.43 | 10.34 | 29.39 | 55.61 |
Tangible Book Value | 576.22 | 89.83 | 60.74 | 130.99 | 290.14 | 603.01 |
Tangible Book Value Per Share | 29.52 | 5.32 | 4.43 | 10.34 | 23.26 | 49.35 |